Ole J. Kaasbøll
Ole J. Kaasbøll, MD, PhD


Dr. Kaasbøll is a licensed MD and has a PhD on the subject of CCN2/CTGF (“Connective Tissue Growth Factor”) signaling. Dr. Kaasbøll isolated the bioactive fragment of CCN2 that had evaded the field for almost 3 decades and established systems for its production.


Since 2017 Dr. Kaasbøll worked in Prof.Attramadal’s laboratory at the Oslo University Hospital on developing what has now become Tribune Therapeutics’ lead molecule, TRX-44, an anti-fibrotic protein therapeutic targeting CCN signaling. Dr. Kaasbøll is a co-founder and the CSO of Tribune Therapeutics